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Abstract
Epstein-Barr virus (EBV) is usually maintained in an asymptomatic and latent form by the
host immune system, and primarily by EBV-specific cytotoxic T cells (CTLs). However, EBV has
been linked to several refractory diseases such as EBV-associated hemophagocytic syndrome(EBV-
AHS) and chronic active EBV infection (CAEBV). In these ectopic diseases, EBV infects T/NK
cells, causing severe immunodeficiency with a very high EBV load. In recent years, the labora-
tory procedure to assess these types of EBV infections has been improved. In particular, real-time
polymerase chain reaction (PCR) has been used to quantify the EBV load, and the MHC: peptide
tetramer assay has been used to quantitate EBV-specific CTLs; these tests have been employed for
the management of the illnesses associated with EBV infection. Here, we have reviewed the recent
progress in the clinical application of these assays. The pathogenesis of EBV-infected T/NK cells,
and the host immune response to infection, including the roles carried out by innate immunity and
inflammatory cytokines, are likely to be revealed in the future.
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Epstein-Barr virus (EBV) is usually maintained in an asymptomatic and latent form by the host immune system, and primarily by EBV-speciﬁc cytotoxic T cells(CTLs). However, EBV has been linked to several refractory diseases such as EBV-associated hemophagocytic syndrome(EBV-AHS)
and chronic active EBV infection (CAEBV). In these ectopic diseases, EBV infects T/NK cells,
causing severe immunodeﬁciency with a very high EBV load. In recent years, the laboratory procedure to assess these types of EBV infections has been improved. In particular, real-time polymerase chain reaction (PCR)has been used to quantify the EBV load, and the MHC:peptide tetramer assay has been used to quantitate EBV-speciﬁc CTLs; these tests have been employed for the management of the illnesses associated with EBV infection. Here, we have reviewed the recent progress in the clinical application of these assays. The pathogenesis of EBV-infected T/NK cells,
and the host immune response to infection, including the roles carried out by innate immunity and inﬂammatory cytokines, are likely to be revealed in the future.
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E pstein-Barr virus (EBV)is a ubiquitous herpes virus, but it can cause refractory diseases that can lead to the need for curative bone marrow transplantation.
The prognosis of patients with such refractory EBV infection depends primarily on the EBV-infected cell type and the state of the host immunity.
During primary infection, EBV typically infects and replicates in B cells. After primary infection, EBV-
speciﬁc T cells(cytotoxic T cells, or CTLs)are usually acquired, which regulate EBV-infected B cells at a rate of 1 to 10?B cells as memory cells. Thus, EBV infection is usually asymptomatic, or else is only occasionally
 
symptomatic as infectious mononucleosis (IM).
However, in a limited number of individuals, EBV infects T/Natural killer(T/NK)cells, which can induce EBV-persistent infection. For example, in patients with chronic active EBV infection (CAEBV), EBV infects primarily CD4?T cells or NK cells［1］. These patients fail to acquire a suﬃcient number of both EBV-speciﬁc and cytomegalovirus(CMV)-speciﬁc CTLs［2］, which is suggestive of T/NK cell dysfunction in the host immune system. This condition leads to a high EBV load and EBV-associated T/NK-cell lymphoproliferative disease.
Patients with EBV-associated hemophagocytic syndrome
(EBV-AHS)also have EBV-infected T cells primarily CD8?cells. EBV-AHS is characterized by the overpro-
duction of inﬂammatory cytokines such as tumor necrosis factorα(TNF-α)and interferon-gamma(IFN-γ), which
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play a central role in the rapid progress of the disease.
EBV-AHS also carries a high mortality rate without immunosuppressive therapy using cyclosporine A and VP-16.
With the available technology, we analyzed cases of complicated EBV infection by monitoring EBV nucleic acid, EBV-speciﬁc CTLs, and virus-associated cyto-
kines. We previously reported a high EBV load in patients with CAEBV［3］and EBV-AHS［4］. Until the present time, monitoring the EBV load has generally been employed for the management of cases involving complicated EBV infection. As regards EBV-speciﬁc CTLs, a major histocompatibility complex (MHC):
tetramer assay has been developed as a revolutionary technology that renders it easy to quantitate virus-speciﬁc CTLs［5］.
Childhood is the period during which humans form adaptive immunity to various viral infections. Thus,
complicated EBV infection may be especially apparent in childhood. This review focuses on the clinical application of these assays mentioned above and on the host immune response to symptomatic EBV infection in childhood.
Quantiﬁcation of EBV DNA using real-time quantitative PCR
 
Due to the patient’s insuﬃcient serologic response to the EBV antigen, EBV antibodies are not useful in immunocompromised individuals such as AIDS patients or bone marrow transplant recipients. Thus, the detec-
tion and quantiﬁcation of EBV nucleic acid is very impor-
tant for assessing the EBV load in these patients. There are 3 methods available for analyzing EBV nucleic acid:
Southern blotting to examine the monoclonality of EBV-
infected cells, in situ hybridization of EBER to identify the EBV-infected cell type, and real-time polymerase chain reaction(PCR)to monitor the EBV load. Real-time PCR of EBV-DNA is especially useful because it can be repeatedly performed after diagnosis to determine the eﬃcacy of therapy. This procedure has several advan-
tages due to its rapidity and simplicity. Recently, real-
time PCR assays using EBV-mRNA have been used in attempts at earlier detection and in the monitoring of reactivation［6］, but the assessment of the actual need for real-time RT-PCR is an issue that will need to be explored in the future.
Our real-time PCR assay method has been described previously［3］. Brieﬂy, peripheral blood mononuclear
 
cells (PBMNCs)were separated with Ficoll-Paque from EDTA-treated blood. To monitor the load of EBV-
DNA, clinicians generally use whole blood［7-9］or PBMNCs［3, 9, 10］, because EBV in peripheral blood is highly associated with leukocytes. However, cell-free EBV-DNA in serum［11-13］or plasma［14］has sometimes been examined, because it reﬂects the EBV load in terms of viral replication. We used a spin-column procedure to extract the DNA from PBMNCs(QIAamp Blood Kit;QIAGEN). We then chose 10??copies/μg DNA as a suitable cut-oﬀlevel for distinguishing EBV-
associated diseases from latent EBV infections or asymptomatic reactivation of the virus. Using a set volume of the DNA extraction solution from a ﬁxed number of PBMNCs is simpler, but may produce a bias caused by diﬀerences in the extraction eﬃciency for each sample. If 10?lymphocytes produce 0.5μg DNA, as suggested in the manufacturer’s handbook, then 500 copies/10?PBMNCs should produce 10??copies/μg DNA, which is slightly greater than our criterion of 10??
copies/μg DNA.
The diﬀerences between positive controls among labo-
ratories is a shortcoming of the real-time PCR assay, as,
for example, the control dilution error and the target region may vary from lab to lab. Standardization of a positive control is thus essential for improving the useful-
ness of real-time PCR. Our target region for the real-time PCR analysis is the BALF5 gene, which encodes the viral DNA polymerase. There remain some questions regarding the target region of EBV-DNA. Internal repeats and Bam HI fragments are not equivalent to variations of EBV. Thus, DNA polymerase regions such as BALF5 and EBNA are thought to be optimal target regions for PCR analysis. In addition, diﬀerent levels of expression of EBV-mRNA between latency and replication should be considered via real-time PCR［6］.
Quantiﬁcation of EBV-speciﬁc cytotoxic T cells
 
Host cellular immunity, especially via virus-speciﬁc CTLs, is closely associated with EBV load. To identify and quantify EBV-speciﬁc CTLs, we have used a major histocompatibility complex (MHC):peptide tetramer assay, an IFN-γ enzyme-linked immunospot
(ELISPOT) assay, and intracellular cytokine staining.
The antigen-speciﬁc T-cell receptor recognizes a complex of an antigenic peptide and a molecule of self-MHC, and
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the aﬃnity of interaction between the T cell and the MHC:
peptide is very low. Thus, before it was possible to use the MHC:peptide tetramer (i.e., the 4 speciﬁc MHC:
peptide complexes bound to a single molecule of strep-
tavidin labeled with a ﬂuorochrome), it was not possible to directly count the number of antigen-speciﬁc T cells
(Fig. 1A)［5］. Kuzushima et al. reported 3 EBV epitopes that were recognized by human leukocyte antigen
(HLA)-A?2402-restricted EBV-speciﬁc CTLs［15］.
Based on their data, MHC:EBV-peptide tetramers of HLA-A?0201 and 2402 are commercially available in Japan (Medical and Biological Laboratories Co., Ltd.,
Nagoya, Japan)(Fig. 1B). HLA-A?0201 is observed in approximately 10-20  of Japanese, and HLA-A?2402 is seen in approximately 37  of Japanese［16, 17］.
These mounting EBV-peptide tetramers are gene prod-
ucts during latency (LMP, EBNA) or replication
(BRLF, BMLF). With an MHC:peptide tetramer assay, virus-speciﬁc CTLs can be measured easily and within a few hours using a ﬂowcytometer(Fig. 1 C).One shortcoming of the tetramer assay is that a patient’s HLA haplotype is restricted. However, due to the convenience of this approach, the MHC:peptide tetramer assay is widely used when treating patients with other viral infec-
tions, such as HIV, CMV, and HBV.
Two other methods can be used without restriction regarding the patient’s HLA haplotype. The ELISPOT assay is a variant of the ELISA assay, in which the number of cytokine-induced antigen-speciﬁc T cells is counted on a plastic surface. Intracellular cytokine stain-
ing using a ﬂowcytometer can be used to detect cytokine production at the single-cell level. The producing cytokine
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Fig. 1  MHC:peptide tetramer assay. A, Structure of MHC class I:peptide tetramer. Recombinant MHC class I molecules with an antigen-speciﬁc peptide are bound to each subunit of streptavidin and are labeled with phycoerythtine(PE), which binds stably to T cells. B,
EBV-speciﬁc MHC tetramers that are commercially available in Japan;C, Staining of cells with the HLA A?2402-restricted EBV tetramers. The tetramer-positive CD8?T cells were detected by ﬂow cytometry.
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accumulates in the endoplasmic reticulum by a metabolic inhibitor, and cytokine-speciﬁc antibodies penetrate the cell to bind to the intracellular cytokine. Intracellular cytokine staining could be applied to so-called double-
positive T cells, such as CD25?CD4 T cells.
Clinical application for EBV-associated diseases
 
The EBV-
infected cell type is B cells in cases of IM, and the primary EBV infection in childhood is usually asymptomatic, although some children and younger adults manifest IM, which occasionally causes serious complica-
tions such as pneumonitis, hepatic failure, rupture of the spleen, and central nervous system involvement. Primary EBV infection can develop into EBV-AHS in a limited number of individuals and may be the ﬁrst symptom of CAEBV［14］.
We previously compared EBV-DNA among patients with IM, CAEBV, and lymphoproliferative disease
(LPD)(Fig. 2)［3］. The mean copies of EBV-DNA in the PBMNCs was 10??copies/μg DNA in patients with IM, 10??copies/μg DNA in patients with CAEBV, and 10??copies/μg DNA in patients with LPD. These numbers were signiﬁcantly larger than those in EBV-
seropositive controls. The reason why patients with IM showed a lower viral load compared with patients with CAEBV or LPD may be a diﬀerence of host immunity.
Patients with IM can acquire virus-speciﬁc CTLs, and the virus load decreases gradually.
During primary EBV infections, it is important to distinguish EBV-AHS from IM. It has been reported that there is a greater EBV load in patients with EBV-
AHS than in those with IM［11］. Cell-free viral DNA,
which reﬂects the EBV load in replication, had been considered to be a useful marker. However, some patients with the onset of EBV-AHS were found to have 10?to 10?copies/ml of EBV-DNA in their plasma,
which is the average viral load in patients with IM.
EBV-DNA in the PBMNCs is apparently higher in these patients, and thus it is considered to be a better marker for distinguishing between these 2 diseases［4］.
EBV-AHS progresses very rapidly and becomes a life-threatening disease without im-
munosuppressive therapy. In EBV-AHS, the hyper-
activation of EBV-infected T cells leads to the subsequent activation of macrophages. The EBV-infected cells are usually CD8?cells, but occasionally they are CD4?T cells or both T-cell populations［18］. The EBV-infected cell type and a high EBV load are considered as the main triggers for EBV-AHS.
These activating cells produce cytokines in too great a quantity, which is referred to as a“cytokine storm”. The cytokine storm causes coagulopathy and multiple organ failure, both of which progress very rapidly. The pos-
tulated cytokine network in EBV-AHS is shown Fig. 3.
Th1-type cytokines (IL-12, IL-2, IFN-γ, and IL-18)
are highly elevated, and in contrast, IL-4 is suppressed
［19, 20］. Two major inﬂammatory cytokines, IFN-γ
and TNF-α, play a central role in the resistance of the
 
Fig.2  Quantitation of EBV DNA by real-time PCR(cited from［3］).
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host to EBV infection, as well as in the activation of macrophages. However, EBV has a mechanism for evading the antiviral function of these cytokines. For example, when EBV infects NK cells, IFN-γmay prevent EBV-infected cells from apoptosis［21］. As regards TNF-α, immediate-early protein BZLF1 inhibits TNF-α-induced signaling and apoptosis by the dow-
nregulation of TNF receptor 1［22］.
These inﬂammatory cytokines are also associated with liver dysfunction, which is a common feature of EBV infection. TNF-αitself can cause liver dysfunction［23］,
but the Fas-ligand greatly aﬀects EBV-associated liver dysfunction［24］. We experienced 1 case with severe hepatitis. This patient’s liver biopsy showed that inﬁltrating CD8?cells, and not hepatocytes, were posi-
tive for EBV, and these EBV-infected lymphocytes expressed Fas-ligand, whereas the hepatocytes expressed Fas-antigens［24］. As regards other cytokines, the elevation of IL-18, which is produced by activated macrophages, has been reported as a useful marker of disease activity in EBV-AHS［25］.
The cytokine proﬁle in EBV-AHS may be slightly diﬀerent from that in CAEBV(Table 1)［20, 26］. For example, transforming growth factor (TGF)-β, which might activate EBV from latency through BZLF1, was elevated in one of our patients with CAEBV［27］. In addition, there are diﬀerences between the 2 types of CAEBV (T cell-type and NK cell-type). That is, the
 
levels of IL-13 are signiﬁcantly higher in patients with NK cell-type CAEBV than in those with T cell-type CAEBV
［26］. IL-13 is a Th2-type cytokine that induces a class switch to IgE and suppresses the cytotoxic function of macrophages.
IL-10, which is an inhibitory factor for IFN-γ,
TNF-α, and IL-6, is also elevated in patients with symptomatic EBV infection. However, its role in EBV infection is complex［28］. EBV contains a homolog of IL-10(viral IL-10), and its function diﬀers slightly from that of cellular IL-10［29］. Viral IL-10 shares many of the immunosuppressive properties of cellular IL-10, but lacks several of its immunostimulatory features, such as increasing the activity of both NK cells as well as CTLs
［28］. Therefore, viral IL-10 would be elevated in patients with CAEBV［30］. Beyond that, allelic polymorphism in the IL-10 gene induces a variation in IL-10 production, and variation of the IL-10 level may inﬂuence the host immunity to EBV infection［31］.
In the early phase of EBV-AHS, EBV infects CD8?
cells, but the role played by EBV-speciﬁc CD8?CTLs remains unclear. Use of the MHC:peptide tetramer assay may help elucidate this role in the future.
In CAEBV, there are more EBV-infected CD4?T cells or NK cells than EBV-infected CD8?T cells. CAEBV is characterized by chronic or recurrent IM-like symptoms persisting over a long period of time and by an unusual pattern of anti-EBV antibodies. The 3 main criteria for CAEBV are:(I) severe illness lasting more than 6 months, which began as a primary EBV infection and
 
Table 1  Comparison of cytokine proﬁles in patients with EBV-AHS and CAEBV
 
Cytokine  EBV-AHS  CAEBV
 




Th2 type IL-10 ↑ ↑(T＞NK)
IL-4 ↓ ↓
IL-13 ? ↑(T＜NK)
Others TGF-β ? ↑
viral IL-10 ? ↑
Fig.3  The putative cytokine network in cases of EBV infection.
Solid arrows indicate stimulatory eﬀects, and dotted arrows indicate inhibitory eﬀects.
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was associated with grossly abnormal EBV antibody titers, anti-viral caused antigens (VCA) IgG ≧5120,
anti-early antigens(EA)IgG≧640, and anti-EB nuclear antigens(EBNA)＜2;(II)histological evidence of major organ involvement such as interstitial pneumonia, hyper-
plasia of some bone marrow elements, ileitis,
lymphadenitis, persistent hepatitis, or splenomegaly;and
(III)increased quantities of EBV in aﬀected tissues［32］.
However, in some cases, patients lacking these abnormal patterns of EBV-related antibodies and major organ involvement have only dermatological symptoms, such as hypersensitivity to mosquito bites or hydroa vacciniforme-
like eruptions［33-35］.
In addition to these reported ﬁndings regarding the clinical criteria, we previously reported the new virologic characteristics of CAEBV［36］. First, we observed a high viral load in the peripheral blood of CAEBV patients
(Fig. 2). Moreover, patients with life-threatening symp-
toms showed a higher viral load than did patients with mild disease severity. The EBV load was found to be associated with the severity of EBV-related disease.
Second, we observed chromosomal aberrations and monoclonality of EBV in more than half of the patients with CAEBV. There was no chromosomal speciﬁcity among the patterns of aberrations that we observed.
Chromosomal aberration was more frequent in NK-cell CAEBV than in T-cell CAEBV. Patients with chromosomal aberrations showed a higher rate of malig-
nancy. However, the probability of survival at 5 years was 0.41±0.18 for patients with T-cell CAEBV and 0.83±0.15 for patients with NK-cell CAEBV, in patients who did not undergo bone marrow transplanta-
tion. The survival rate was also associated with the age of the patient upon the onset of disease. Patients who were older than 8 years at the time of disease onset had a signiﬁcantly poorer prognosis［37］. Prognostic factors for CAEBV are summarized in Table 2.
CAEBV is not only a premalignant condition, but is also a condition involving severe immunodeﬁciency. Most CAEBV patients examined had an insuﬃcient number of EBV-speciﬁc CTLs, as determined by a MHC:peptide tetramer assay using both lytic and latent proteins［2］. In particular, latent membrane 2(LMP-2)-speciﬁc CD8?T cells were not detected in any of these patients. LMP-2 is expressed in EBV-infected cells in CAEBV patients,
and thus LMP-2 expression may be involved in the mechanism that enables EBV to evade host immunity
［2］. A suﬃcient number of EBV-speciﬁc CTLs is the
 
most important factor in the cure of CAEBV infection.
We previously reported our observation that EBV-
speciﬁc CTL adoptive immune therapy is potentially useful in cases of severe CAEBV infection［38］.
Adoptive immune therapy is deﬁned as the infusion of immune eﬀector cells, such as EBV-speciﬁc CTLs, for the treatment and/or prevention of disease［39］. Brieﬂy,
an EBV-speciﬁc CTL line, which is established from PBMCs obtained from an HLA-matched donor, is trans-
fused to the patient(Fig. 4). In our experience, after the transfusion of EBV-speciﬁc CTLs, cell-free EBV-DNA showed transient but repeated decreases associated with increases in anti-EBV CTL activity.
The pathogenesis of CAEBV remains largely obscure.
Initially, CMV-speciﬁc CTLs were not observed in CMV-seropositive CAEBV patients［2］. The reason why the host immunity to CMV is also suppressed in CAEBV patients is also unclear. In addition, little is
 
Table 2  Factors associated with prognosis for patients with CAEBV
(modiﬁed from［37］)
Factor  5-years survival
 
Age at disease onset
＜8 years  0.94±0.04%




EBV-infected cell type NK cell type  0.87±0.07%
T cell type  0.59±0.09%
Fig.4  Scheme for CTL adoption(cited from［38］).
Yamashita et al. Acta Med. Okayama Vol. 59 , No. 6 244
6
Acta Medica Okayama, Vol. 59 [2005], Iss. 6, Art. 1
http://escholarship.lib.okayama-u.ac.jp/amo/vol59/iss6/1
 known about how EBV is capable of infecting T/NK cells that do not express CD21. It is possible that after the early activation of T/NK cells by conjugation to CD21?
B-EBV cells, these cells transiently acquire a weak CD21?phenotype［40］. Yet another factor that remains unclear is why CAEBV occurs more often in Asian countries than in Western countries. The perforin gene mutation revealed in EBV-AHS and CAEBV patients may be related to this racial diﬀerence［41, 42］.
Calciﬁcation of the bilateral basal ganglia, which is a common feature in HIV patients, has also been reported in patients with CAEBV［43］. NK cell proliferation and TNF-αmay also be involved in its pathogenesis［44］.
Here, we reviewed recent prognoses in order to evaluate complicated EBV infection(Table 3). In addition to EBV-induced tumorigenesis, an overproduction of cytokines in cases of EBV-AHS and a weak host immune response such as CAEBV can be fatal, especially in children. Future analysis of host immunity, including innate immunity, may help establish the optimum therapy for these complicated and refractory EBV infections.
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Table 3  Summary of EBV loads and host immunity in patinets with IM, EBV-AHS, and CAEBV
 
Disease  EBV-infected cell  EBV load and Host immunity
 
Infectious Mononucleosis (IM) B cell  EBV load at onset is about 10??copy
/ug/DNA(PBMC), and it disappears within 4-5 weeks after normal increase of EBV-CTL.
EBV-associated hemophagocytic lympho proliferative syndrome(EBV-AHS)
T cell (mainly CD8?,
occationaly CD4?or both phenotypes)
EBV load is usually more than 10??copy/ug/DNA(PBMC), but sometimes at the same level as IM. It gradually decrease, although can be detected 3 months after remission. An overproduction IFN-γ,
TNF-α, IL-10 and IL-12 which is called a cytokine storm causes a rapid progress of EBV-AHS. The role of EBV-CTL has been unknown yet.
-
Chronic active EBV infection(CAEBV) T cell(mainly CD4?), NK cell
 
The average of EBV is 10?copy/ug/DNA(PBMC)that is the same level as LPD. EBV load doesn’t decrease because of insuﬃcient EBV-CTLs. Host immunodeﬁciency are not only related to EBV but other viruses, such as CMV.
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